References
- Adhami ZN, Wise R, Weston D, Crump b The pharmacokinetics and tissue penetration of norfloxacin. J Anlimicrob Chemother. 198513: 87 92.
- Downs J, Andriole V, Ryan JL. In vitro activity of MKO 366 against clinical urinary pathogens including gcntamicin resistant pseudomonas. Antimicrob Ag Chemother. 1982; 21: 670–2.
- Duckworth GJ, Williams JD. Frequency of appearance of resistant variants to norfloxacin and nalidixic acid. J Antimicrob Chemother. 1985; 13: Suppl. B. 33–8.
- Giamarellou H, Tsargarakis J, Petrikkos G, Daikos GK. Norfloxacin versus cotrimoxazole in the treatment of lower urinary tract infections. Eur J Clin Microb. 1983; 2: 266 9.
- Guerra JG, Falconii E, Palomino JC, Benavente L. Atunez de.Clinical evaluation of nor floxacin versus cotrimoxazole in urinary tract infections. Eur J din Microbiol. 1983; 2: 260 5.
- Ito A, Hirai K, Inoue M et al. In vitro activity of AM 715, a new nalidixic acid analog. Antimicrob Ag Chemother. 1980; 17: 103–8.
- Jones RN, Barry AL. Norfloxacin (MK-0366, AM-715) in vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing. Diagn Microb Infect Dis. 1983; 1: 165–72.
- Kahn MY, Gruninger RP, Nelson S, Klicker RE. Comparative in vitro activity of norfloxacin and ten other antimicrobial agents against urinary tract bacterial isolates. Antimicrob Ag Chemother. 1982; 21: 848–51.
- King A, Warren C, Shannon K, Philips I. In vitro activity of norfloxacin (MK 366). Antimicrob Ag Chemother. 1982; 21: 604–7.
- Leigh DA, Emmanuel FXS. The treatment of Pseudomonas aeruginosa urinary tract infection with norfloxacin. J Antimicrob Chemother. 1984; 13, Suppl. B: 85–8.
- Neu HC, Labthavikul P. In vitro activity of norfloxacin a quinoline-carboxyl acid, compared with that of beta-lactams, aminoglycosides and trimethoprim. Antimicrob Ag Chemother. 1982; 22: 23–7.
- Norrby SR. Pharmacokinetics of norfloxacin: clinical implications. Eur J Chemother Antibiotics. 1983; 3: 19–25.
- Revers DS, Lacey RW, Mummery RV, Mahendra M. Bint AJ, Newson SWB. Treatment of acute urinary infection by Norfloxacin or nalidixic acid/citrate: a multicenter comparative study. J Antimicrob Chemother. 1984; 13, Suppl. B: 99–105.
- Shungu DL, Weinberg E, Gadebush HH. Tentative interpretative standards for disk diffusion susceptibility testing with norfloxacin (MK-0366, AM-715). Antimicrob Ag Chemother. 1983; 23: 256 60.
- Swanson BN, Boppana VK, Vlasses PH, Rotmensch HH, Ferguson RK. Norfloxacin disposition after sequentially increasing oral doses. Antimicrob Ag Chemother. 1983; 23: 284–8.
- Watt B, Chait I, Kelsey MC et al. Norfloxacin versus cotrimoxazole in the treatment of uncomplicated urinary tract infections—a multicentre trial. J Antimicrob Chemother. 1984; 13, Suppl. B: 89–94.